Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 5,059 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Multiple Sclerosis
Interventions: MD1003 100mg capsule, PLACEBO; Drug
Lead sponsor: MedDay Pharmaceuticals SA; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 642 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 40
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Berkeley, California + 35 more

Conditions: Nicotine Dependence
Interventions: Intravenous Nicotine, Progesterone; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 40 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Fragile X Syndrome
Interventions: Gaboxadol, Placebo; Drug
Lead sponsor: Craig Erickson; Other
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy
Interventions: Dabigatran etexilate (DE), Rosuvastatin, PF-07081532; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Dry Eye, Contact Lens Complication
Interventions: HydroEye®; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Mantle Cell Lymphoma
Interventions: lenalidomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 31
States / cities: Little Rock, Arkansas • La Jolla, California • Loma Linda, California + 27 more

Conditions: Healthy, Narcolepsy
Interventions: MK-6552, MK-6552 placebo, Modafinil, Modafinil placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 2
States / cities: Atlanta, Georgia • Eatontown, New Jersey

Conditions: Peripheral Arterial Disease
Interventions: Pro-Omega, Pro-Omega Placebo; Dietary Supplement · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years to 90 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Refractory Depression, Treatment Resistant Depression
Interventions: psilocybin; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hypertension
Interventions: Carvedilol CR capsules, Placebo, Lisinopril; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 65 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 20
States / cities: Anniston, Alabama • Glendale, Arizona • Anaheim, California + 17 more

Conditions: Healthy Volunteers
Interventions: Venglustat; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 2
States / cities: Miami, Florida • Saint Paul, Minnesota

Conditions: Adenocarcinoma of the Pancreas
Interventions: MK-1775, Gemcitabine, Radiation Therapy; Drug · Radiation
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Osteoporosis
Interventions: BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene 60 mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 22
States / cities: Fort Myers, Florida • Gainesville, Florida • New Port Richey, Florida + 19 more

Conditions: Down Syndrome, Intellectual Disability
Interventions: Memantine, Placebo; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 15 Years to 32 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Smoking Cessation, Tobacco Use Disorder
Interventions: EMB-01; Drug
Lead sponsor: Rose Research Center, LLC; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Ductal Breast Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer
Interventions: oral placebo, afimoxifene, tamoxifen citrate, placebo gel; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Immune System Disorder, Healthy Volunteers
Interventions: Belumosudil, UGT1A1 victim drug, P-gp victim drug, OATP1B1/BCRP victim drug; Drug
Lead sponsor: Kadmon, a Sanofi Company; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: PreDiabetes
Interventions: Low-dose bitter melon, High-dose bitter melon, Placebo; Dietary Supplement
Lead sponsor: Midwest Center for Metabolic and Cardiovascular Research; Other
Eligibility: 18 Years to 74 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 3
States / cities: Miami Gardens, Florida • Port Saint Lucie, Florida • Addison, Illinois

Conditions: Aspirin Exacerbated Respiratory Disease (AERD)
Interventions: Ifetroban, Oral Capsule, Placebo, Oral Capsule; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: San Diego, California • Overland Park, Kansas • West Nyack, New York

Conditions: Cognitive Impairment, Cognitive Decline, Cognition Disorders in Old Age, Well-Being, Psychological, Inflammation, Cognitive Fun
Interventions: LasoperinTM, Placeo; Dietary Supplement
Lead sponsor: Lindenwood University; Other
Eligibility: 30 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Refractory Follicular Lymphoma, Relapsed Follicular Lymphoma
Interventions: Ibrutinib, Venetoclax; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Hackensack, New Jersey • Seattle, Washington

Conditions: Thyroid Neoplasms, Poorly Differentiated and Undifferentiated Thyroid Cancer, Differentiated Thyroid Cancer
Interventions: CUDC-907; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: BRAFV600E Melanoma Patients
Interventions: Dabrafenib, Gamma Knife Radiosurgery, Trametinib; Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Relapsed/Refractory Peripheral T-cell Lymphoma
Interventions: Tolinapant, Decitabine + Cedazuridine; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: Aurora, Colorado • Tampa, Florida • Atlanta, Georgia + 3 more

Search by objective public record fields.

Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)

Effects of Progesterone on IV Nicotine-Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effect

Placebo-Controlled, Single-Dose Challenge Study of Gaboxadol in Adult Males With Fragile X Syndrome (FXS)

A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants

Effects of Supplementation With PUFAs and Antioxidants for Contact Lens Discomfort

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

A Study of MK-6552 in Sleep Deprived Healthy Participants (MK-6552-003)

The Use of Fish Oil to Reduce Inflammation Caused by a Peripheral Vascular Intervention

Psilocybin-Assisted Therapy in Treatment-Resistant Depression

Evaluation of Potential for Orthostatic Hypotension in Elderly Hypertensives

A Study of the Safety, Tolerability, and Bioequivalence of Orally Administered Venglustat in Healthy Adult Participants

Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas

Study Evaluating Changes In Mammographic Breast Density

Down Syndrome Memantine Follow-up Study

Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment

4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ

A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects

Effects of Bitter Melon on Cardiometabolic Health

Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease

A Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of LasoperinTM on Cognitive Function in Healthy Adults

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer

Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets

A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)